Logotype for Verastem Inc

Verastem (VSTM) investor relations material

Verastem H.C. Wainwright 27th Annual Global Investment Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Verastem Inc
H.C. Wainwright 27th Annual Global Investment Conference summary8 Sep, 2025

Key product launches and commercial progress

  • Achieved accelerated FDA approval for avutometinib plus defactinib in low-grade serous ovarian cancer, with a 44% response rate in pivotal study and over $2 million net sales in the first six weeks post-launch.

  • Strong momentum continues into the first full quarter, with positive feedback from physicians and patients.

  • No immediate plans for Canada; regulatory discussions ongoing in Europe and Japan, with a bridging study in Japan nearing full accrual and potential conditional approval targeted for 2027.

Clinical development and pipeline updates

  • Confirmatory Phase 3 trial in ovarian cancer is nearly fully accrued, with a pre-planned interim analysis expected later this year to assess sample size and study direction.

  • Expansion of avutometinib plus defactinib into other indications, including G12C non-small cell lung cancer (in partnership with Amgen) and frontline metastatic pancreatic cancer, with 83% response rate in the latter.

  • VS-7375, a dual on-off KRAS G12D inhibitor, shows promising data from partner GenFleet Therapeutics: 52% response rate in pancreatic cancer and 69% in lung cancer at recommended dose.

  • U.S. Phase 1 for VS-7375 is progressing rapidly, with safety data expected later this year and initial efficacy data in the first half of next year; combination regimens to begin soon.

Financial position and strategic outlook

  • Cash position over $160 million, with an additional $50 million expected from in-the-money warrants, providing runway into the second half of 2026.

  • LGSOC business could become self-funding by 2026; future funding for G12D program may come from sales, partnerships, or equity raises, with partnerships preferred over dilution.

  • Additional line of credit available but not yet drawn; financial strategy will adapt to data, sales, and macroeconomic conditions.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Verastem earnings date

Logotype for Verastem Inc
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Verastem earnings date

Logotype for Verastem Inc
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Verastem Inc is a development-stage biopharmaceutical company primarily focused on the development and commercialization of new medicines aimed at improving the lives of patients diagnosed with cancer. The company is engaged in advancing a pipeline of novel small-molecule drugs that target critical signaling pathways involved in cancer cell survival and tumor growth. These pathways include RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition, which are central to the company's research and development efforts. The company is headquartered in Needham, Massachusetts, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage